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Abstract
BACKGROUND: Pulmonary veno-occlusive disease (PVOD) is an uncommon
form of pulmonary hypertension characterized by the obstruction of small
pulmonary veins and a dismal prognosis. PVOD may be sporadic or heritable
because of biallelic mutations of the EIF2AK4 gene coding for GCN2. Isolated
case reports suggest that chemotherapy may be a risk factor for PVOD.
METHODS AND RESULTS: We reported on the clinical, functional, and
hemodynamic characteristics and outcomes of 7 cases of PVOD induced by
mitomycin-C (MMC) therapy from the French Pulmonary Hypertension Registry.
All patients displayed squamous anal cancer and were treated with MMC alone or
MMC plus 5-fluoruracil. The estimated annual incidence of PVOD in the French
population that have anal cancer is 3.9 of 1000 patients, which is much higher
than the incidence of PVOD in the general population (0.5/million per year). In
rats, intraperitoneal administration of MMC induced PVOD, as demonstrated by
pulmonary hypertension at right-h...
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Pulmonary veno-occlusive disease (PVOD) is a rare and devastating cause of pulmonary hypertension (PH). PVOD 
is characterized by widespread fibrous intimal proliferation of 
septal veins and preseptal venules, and is frequently associ-
ated with pulmonary capillary dilatation and proliferation.1 
Although the pathology firmly confirms PVOD, a noninva-
sive diagnostic approach is usually favored in these fragile 
patients in whom a lung biopsy carries a high risk of life-
threatening complications. Decreased diffusing capacity of 
the lung for carbon monoxide, severe hypoxemia, radiological 
abnormalities on high-resolution computed tomography (CT) 
scans of the chest, and the occurrence of pulmonary edema 
after starting pulmonary vasodilator therapy strongly argue for 
PVOD.1,2 PVOD is a difficult form of PH to diagnose; it is fre-
quently misclassified as idiopathic pulmonary arterial hyper-
tension (PAH). Thus, the true incidence of PVOD is not known 
precisely, but is considered to represent 10% of cases of PAH 
Background—Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonary hypertension characterized 
by the obstruction of small pulmonary veins and a dismal prognosis. PVOD may be sporadic or heritable because of 
biallelic mutations of the EIF2AK4 gene coding for GCN2. Isolated case reports suggest that chemotherapy may be a risk 
factor for PVOD.
Methods and Results—We reported on the clinical, functional, and hemodynamic characteristics and outcomes of 7 cases 
of PVOD induced by mitomycin-C (MMC) therapy from the French Pulmonary Hypertension Registry. All patients 
displayed squamous anal cancer and were treated with MMC alone or MMC plus 5-fluoruracil. The estimated annual 
incidence of PVOD in the French population that have anal cancer is 3.9 of 1000 patients, which is much higher than 
the incidence of PVOD in the general population (0.5/million per year). In rats, intraperitoneal administration of MMC 
induced PVOD, as demonstrated by pulmonary hypertension at right-heart catheterization at days 21 to 35 and major 
remodeling of small pulmonary veins associated with foci of intense microvascular endothelial-cell proliferation of the 
capillary bed. In rats, MMC administration was associated with dose-dependent depletion of pulmonary GCN2 content 
and decreased smad1/5/8 signaling. Amifostine prevented the development of MMC-induced PVOD in rats.
Conclusions—MMC therapy is a potent inducer of PVOD in humans and rats. Amifostine prevents MMC-induced PVOD 
in rats and should be tested as a preventive therapy for MMC-induced PVOD in humans. MMC-induced PVOD in rats 
represents a unique model to test novel therapies in this devastating orphan disease.  (Circulation. 2015;132:834-847. 
DOI: 10.1161/CIRCULATIONAHA.115.014207.)
Key Words: alkylating agents ◼ antineoplastic agents ◼ complications ◼ drug-related side effects and adverse reactions  
◼ GCN2 ◼ hypertension, pulmonary ◼ pulmonary veno-occlusive disease 
© 2015 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.115.014207
Received October 2, 2014; accepted June 22, 2015.
From Univ. Paris–Sud, Faculté de Médecine, Kremlin-Bicêtre, France (F.P., S.G., B.R., L.G., F.A., P.D., A.H., N.R., L.S., X.J., B.G., O.S., G.S., M.H., 
D.M.); AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation (TORINO), 
Service de Pneumologie, Hôpital de Bicêtre, Le Kremlin Bicêtre, France (F.P., S.G., B.R., L.G., F.A., A.H., L.S., X.J., B.G., O.S., G.S., M.H., D.M.); 
UMR_S 999, Univ. Paris–Sud, INSERM, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), 
Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France (F.P., S.G., B.R., L.G., F.A., M-C.C., P.D., H.R., L.S., X.J., B.G., O.S., G.S., M.H., 
D.M.); Univ. Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France (M-C.C.); Pulmonary Hypertension Research Group, Centre de Recherche de 
l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Canada (F.P.); Service de Pneumologie, CHU Mont-Godinne - 
Université Catholique de Louvain, Yvoir, Belgium (L.G.); AP-HP, Service de Pharmacie, Département Hospitalo-Universitaire (DHU) Thorax Innovation, 
Hôpital Antoine Béclère, Clamart, France (M-C.C.); Department of Pathology, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France (P.D.); 
and National Reference Centre for Rare Pulmonary Diseases, Department of Respiratory Medicine, Louis Pradel Hospital, Lyon, France (V.C.).
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA. 
115.014207/-/DC1.
Correspondence to David Montani, MD, PhD, AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Service de Pneumologie et Réanimation 
Respiratoire, DHU Thorax Innovation, Hôpital de Bicêtre, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France. E-mail david.montani@bct.aphp.fr
Mitomycin-Induced Pulmonary Veno-Occlusive Disease
Evidence From Human Disease and Animal Models
Frédéric Perros, PhD; Sven Günther, MD; Benoit Ranchoux, PhD; Laurent Godinas, MD;  
Fabrice Antigny, PhD; Marie-Camille Chaumais, PharmD, PhD; Peter Dorfmüller, MD, PhD;  
Aurélie Hautefort, PhD; Nicolas Raymond, MSc; Laurent Savale, MD, PhD; Xavier Jaïs, MD;  
Barbara Girerd, PhD; Vincent Cottin, MD, PhD; Olivier Sitbon, MD, PhD;  
Gerald Simonneau, MD; Marc Humbert, MD, PhD; David Montani, MD, PhD
Clinical Perspective on p 847
 at Bibliotheques de l'UCL on January 15, 2016http://circ.ahajournals.org/Downloaded from 
Perros et al  Mitomycin-Induced PVOD  835
that were initially considered as idiopathic or heritable, thus 
suggesting an incidence of <0.5/million per year.2,3
The pathophysiological mechanisms of PVOD remain 
poorly understood, in particular, because of the lack of ani-
mal models conducted on PVOD. PVOD may also be heri-
table and associated with biallelic mutations in the Eukaryotic 
Translation Initiation Factor 2 Alpha Kinase 4 (EIF2AK4) 
gene that codes for general control nonderepressible 2 protein 
(GCN2).4 Isolated case reports suggest that chemotherapeu-
tic agents may induce the development of PVOD.5 However, 
PVOD is usually reported in patients receiving multiple regi-
mens of chemotherapy, making it difficult to individualize 
drugs or pathophysiological mechanisms.
We have recently published systematic analysis and the 
experience of the French PH network, which suggests that 
alkylating agents may represent the predominant chemothera-
peutic class of drugs associated with PVOD.6 The French PH 
Network, which includes specialized pulmonary vascular cen-
ters, has now facilitated a study on the trends of PH and has 
developed a pharmacovigilance program at national level.7–9 
Since 2012, any cases of severe PVOD that have occurred in 
the setting of anal cancer and after therapy with mitomycin-C 
(MMC) have been identified in the French PH Registry and 
reported to the French pharmacovigilance agency. The present 
report summarizes the clinical characteristics and outcomes 
of 7 cases of MMC-associated PVOD identified in the French 
Registry. To confirm a causal link between MMC and human 
PVOD, we demonstrated that in rats, MMC induced specific 
remodeling of pulmonary venous and capillary compartments, 
representing a unique animal model of human PVOD. We 
have also demonstrated a preventive effect of amifostine, a 
cytoprotective agent, in animal models.6
Methods
Patients
We prospectively collected the clinical, functional, and hemodynamic 
characteristics and outcomes of PVOD associated with MMC therapy 
from the French PH Registry. The registry was established in accor-
dance with the French bioethics laws (Commission Nationale de 
l’Informatique et des Libertés) and all patients gave their informed con-
sent. Diagnosis of precapillary PH, defined as a mean pulmonary arte-
rial pressure (mPAP) ≥25 mm Hg with a normal pulmonary capillary 
wedge pressure (PCWP) of ≤15 mm Hg, was confirmed in all patients 
by right heart catheterization. Right atrial pressure, mPAP, PCWP, 
and mixed venous oxygen saturation were recorded. Cardiac output 
(CO) was measured by using the standard thermodilution technique. 
Pulmonary vascular resistance was calculated as (mPAP–PCWP)/CO, 
expressed in Wood units. Acute vasodilator testing was performed dur-
ing right heart catheterization by using inhaled nitric oxide, as pre-
viously described.10 Routine evaluation at baseline included medical 
history, physical examination, echocardiography, high-resolution CT 
of the chest, ventilation/perfusion lung scan, abdominal ultrasound, 
autoimmunity screening, and human immunodeficiency virus (HIV) 
serology. Age at diagnosis, modified New York Heart Association 
functional class, and 6-minute walk distance were also recorded. All 
patients tested for BMPR2 and EIF2AK4 mutations received genetic 
counselling and signed written informed consent.
Number of cycles of MMC therapy, associated chemotherapeutic 
agents, delay between the last dose of MMC and diagnosis of PVOD, 
and outcomes were collected.
In Vivo Study Design
Rats were housed at the Faculty of Pharmacy of Châtenay-Malabry 
(ANIMEX platform, Châtenay Malabry, France). Experiments were 
conducted according to the European Union regulations (Directive 
86/609 EEC) for animal experiments and complied with our institu-
tion’s guidelines for animal care and handling. The animal facility is 
licensed by the French Ministry of Agriculture (agreement no. B92-
019-01). This study was approved by the Committee on the Ethics of 
Animal Experiments CEEA26 CAP Sud. Animal experiments were 
supervised by Dr Frederic Perros (agreement delivered by the French 
Ministry of Agriculture for animal experiment no. A92–392). All 
efforts were made to minimize animal suffering.
Male and female Wistar rats (Janvier, 8 weeks old) were subjected 
to different protocols to evaluate sex differences, dose–response rela-
tionships, and the kinetics of PH development after MMC exposure.
Protocol 1: Sex-Specific Susceptibility
Male and female rats were randomly divided into saline (control, n=5) 
or MMC-exposed groups (Ametycin, Sanofi, 4 mg/kg IP, n=10). We 
performed hemodynamic measurements and assessed right ventricle 
hypertrophy, and tissues were collected at 24 days after the injection.
Protocol 2: Dose–Response Relationships 
Females, which harbored a more severe response to MMC (than 
males), were used to study MMC-induced pulmonary vasculopathy 
induced by fractioned lower doses. Rats were randomly divided into 
saline (control, n=5) or MMC-exposed groups: ie, 2 and 3 mg∙kg–1∙wk–1 
for 2 weeks (IP, n=10 for each dose). Rats were euthanized at 30 days 
after the first injection. Hemodynamic measurements were made, right 
ventricle hypertrophy was assessed, and tissue samples were collected.
Protocol 3: Kinetics of PH Development 
Female rats were randomly divided into saline (control, n=5) or MMC-
exposed groups (3 mg∙kg–1∙wk–1 for 2 weeks, IP, n=10). We evaluated the 
hemodynamics using echocardiography at baseline, and at 1, 2, 3, 4, and 
5 weeks after the first MMC injection (n=5–10 rats for each time point).
Protocol 4: Prevention Study 
Amifostine was given IP at 200 mg/kg 30 minutes before 3 mg∙kg–
1∙wk–1 for2 weeks of MMC (n=15). This group was compared with 
the MMC-only exposed group (MMC, 3 mg∙kg–1∙wk–1 for 2 weeks, 
n=25). Survival was evaluated over 5 weeks. Survivors were eutha-
nized at 5 weeks after the second MMC injection and assessed for 
hemodynamic, RV hypertrophy measurements, and tissue collection. 
For information about the choice of MMC doses used in this study, 
see the online-only Data Supplement.
Hemodynamic Measurements, Evaluation of Right 
Ventricle Hypertrophy, and Collection of Tissues
Rats were anesthetized with isoflurane (2 L/min O2/3% isoflurane; 
Minerve, Esternay, France). Hemodynamic measurements were 
recorded with a PowerLab 4/35 data-acquisition system and analyzed 
with LabChart software (AD-Instruments, Oxford, UK).
In anesthetized rats, blood from the ventral-tail artery was taken 
for serum analyses before the hemodynamic measurements. A 3.5F 
umbilical-vessel catheter (Tyco, Plaisir, France) was introduced into 
the right external jugular vein. With the angle directed anteriorly, the 
catheter was inserted 2.5 cm proximally into the right atrium. The 
catheter was then rotated 90° anticlockwise and advanced 1 cm dis-
tally into the right ventricle (RV) and finally into in the pulmonary 
artery after an additional 1.5-cm advancement. Correct anatomic 
placement was confirmed by respective pressure contours. A T-type 
Ultra-Fast Thermocouple Probe (IT-23) was inserted into the left 
carotid artery to allow measurement of CO by the thermodilution 
technique, after the injection of cold saline into the pulmonary artery. 
Data mPAP in mm Hg, CO in mL/min, and total pulmonary resis-
tances in Wood units were subject to statistical analyses.
Following exsanguination, the hilum of the left lung was ligated, 
and the right lung was distended by infusion of formalin via the tra-
chea, and then embedded in paraffin. The noninflated left lung was 
snap-frozen in liquid nitrogen and used for protein quantification. 
The Fulton index for right ventricle hypertrophy, ie, the ratio of right 
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ventricular weight divided by left ventricular (LV) plus septal weight 
(RV/LV+S), was calculated.
Quantification of Pulmonary Microvessel 
Neomuscularization
Morphological assessment of pulmonary vascular remodeling is 
depicted in the online-only Data Supplement.
Hemodynamic Evaluation by Echocardiography
Rats were evaluated by transthoracic echocardiography (Vivid E9, GE 
Healthcare) by using a high-frequency transducer (12 S-D 4-12MHz, 
GE Healthcare). Evaluation was performed under general anesthesia 
and spontaneous breathing (isoflurane induction 4% at room air plus 
isoflurane maintenance 2% at room air). Pulmonary-artery accelera-
tion time,11 CO, and RV dilatation assessed by the ratio between the 
RV and LV and RV wall thickness were assessed according to guide-
lines from RV echocardiographic measurements.12 All data were 
averaged during 5 cardiac cycles.
Histology and Special Stains
Hematoxylin-eosin, hematoxylin-eosin-safran, and orcein stains, and 
α-smooth muscle actin (clone 1A4, Sigma-Aldrich, Lyon, France) 
or proliferating cell-nuclear antigen (clone PC10, Dako, Les Ulis, 
France) immunohistochemical stains were applied to 5-μm-thick 
paraffin-embedded lung sections or 10-μm frozen sections by using 
a routine procedure.
Retrograde Microbead Injection From the LV
Following exsanguination, a catheter was introduced into the LV via 
the aorta and tied to the aorta. Then polystyrene microbeads (10 μm 
diameter; Polysciences, Warrington, PA), suspended in bovine serum 
albumin 20% (Sigma Aldrich, St-Louis, MO), was injected into the 
LV until the pulmonary veins became colored. The lungs were then 
inflated via the trachea with optimal cutting temperature compound 
diluted in phosphate-buffered saline, and then frozen in dry-ice–cold 
isopentane, as previously described.13
Proliferation Assay In Vivo
To examine cell proliferation in rats, we visualized the incorporation 
of exogenously supplied 5-ethynyl-2′-deoxyuridine (EdU) to identify 
cells that underwent DNA replication. EdU was injected intraperito-
neally into the rats at 5 μg/g, at 72 hours before they were euthanized. 
EdU staining was performed by using a Click-iT EdU Alexa Fluor 
488 Imaging Kit (Life Technologies, Saint Aubin, France) on frozen 
sections, according to the manufacturer’s instructions. To charac-
terize EdU-positive cells, we performed double immunostains with 
rabbit anti-CD34 (Ref ab81289, Abcam, Paris, France) and FITC-
labeled anti-α-small muscle actin fluorescein isothiocyanate (clone 
1A4, Sigma-Aldrich, Lyon, France) after EdU staining. Sections were 
viewed under a LSM 700 microscope (Carl Zeiss, Le Pecq, France) 
equipped with 405-, 488-, 555-, and 639-nm lasers (Carl Zeiss). 
Images were recorded and analyzed with ZEN software (Carl Zeiss).
Quantification of BMPRII and GCN2 Lung 
Expression by Western Blotting
Lung-tissue samples from rats and humans were prepared in lysis 
buffer containing 1% Igepal, 20 mmol/L Tris-HCl, 137 mmol/L 
NaCl, 10% glycerol, 2 mmol/L EDTA, 1 mmol/L Na3VO4, leupeptin 
10 μg/μL, lepstatine 10 μg/μL, aprotinin 10 μg/μL, and a prote-
ase-inhibitor cocktail (aprotinin, leupeptin, and Pefabloc [Roche, 
Meylan, France]). Protein lysates (40 μg) were separated on sodium 
dodecyl sulfate polyacrylamide gel electrophoresis and transferred to 
a polyvinylidene fluoride membrane. After blocking, the membranes 
were incubated in Tris-buffered saline with Tween and 5% nonfat 
milk overnight at 4°C with the primary antibodies, BMPRII (Ref 
MA515827, 1/1000, Thermo Scientific), GCN2 (Ref 3302, 1/1000, 
Cell Signaling, Danvers, MA), and phospho-smad1/5/8 (Ref D5B10, 
1/800, Cell Signaling), and the mouse monoclonal antibody against 
β-actin (Sigma), diluted to 1:2000. Blots were incubated with horse-
radish peroxidase–conjugated goat anti-mouse diluted to 1:10 000 
(Cell Signaling) or with horseradish peroxidase–conjugated goat anti-
rabbit diluted to 1:5000 (Cell Signaling), respectively. Antibodies 
were revealed by using enhanced chemiluminescence (Perkin Elmer). 
ImageJ software (http://rsb.info.nih.gov/ij/) was used to quantify the 
level of protein expression.
Construction of Network Pathways
We used Ingenuity Pathway Analysis (Qiagen, Redwood City, CA) as 
previously described.14
Statistical Analyses
Comparisons were made by using the Mann-Whitney (compari-
son between 2 groups) or Kruskal-Wallis (comparison between >2 
groups) test, followed by the Dunn test. To compare the survival 
between the 2 groups, the log-rank test was used. P values of <0.05 
were considered to be statistically signiﬁcant.
Results
Description of MMC-Induced PVOD in the French 
PH Registry
We identified 7 cases of MMC-induced PVOD in the French 
PH Registry between June 2012 and December 2014. All 
patients presented with a diagnosis of squamous anal cancer; 
2 of them were treated with MMC alone and 5 were treated 
with MMC plus 5-fluorouracil. A diagnosis of severe PVOD 
was definitively established in all patients based on clinical, 
functional, radiological, and hemodynamic characteristics 
(Table, Figure 1). All patients were tested for HIV infection, 
a common risk factor for PAH and anal cancer, and 1 test was 
positive (patient 2). No patient underwent a histological pro-
cedure because a lung biopsy was contraindicated in these 
fragile patients and lung transplantation was not proposed 
owing to the recent history of anal cancer.1 The median age 
of patients was 53 years (range, 42–59) with a predominance 
of females (n=6). The delay between the end of chemotherapy 
with MMC and the diagnosis of PVOD was 4 months (range, 
2–12 months). Patients received between 2 and 4 cycles of 
chemotherapy except for one who also received 8 cycles of 
5-fluorouracil plus oxaliplatin (Table).
At diagnosis, patients with MMC-induced PVOD had 
severe clinical, functional, and hemodynamic symptoms. 
Patients were within New York Heart Association functional 
class III (n=4) or IV (n=3). Severe hypoxemia and a low diffus-
ing capacity of the lung for carbon monoxide were observed in 
all patients (Table). Brain natriuretic peptide was increased at 
diagnosis in all patients (median, 951 ng/L; range, 452–1536 
[normal value <100 ng/L]). Echocardiography suggested PH, 
impairment of RV function, and an absence of left heart dys-
function. Right-sided heart catheterization confirmed severe 
precapillary PH with a median mPAP of 41 mm Hg (range, 
36–64 mm Hg), a decreased cardiac index of 2.1 L∙min–1∙m–² 
(range, 1.6–4), and normal PCWP of <15 mm Hg in all patients. 
Median pulmonary vascular resistance was 11.2 Wood units 
(range, 5.5–13.6). High-resolution CT of the chest identified 
septal lines, centrilobular ground-glass opacities, and lymph 
enlargement in all patients (Figure 1). Pleural effusions were 
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present in 2 of the 7 patients, but no cardiac effusions were 
observed. Genetic screening for EIF2AK4 and BMPR2 muta-
tions was performed in 4 patients, and identified no mutations. 
Because of the severely impaired hemodynamic parameters 
and the contraindication for lung transplantation, specific PAH 
therapies were introduced either as a monotherapy (n=2) or as 
a combination of endothelin-receptor antagonists and phos-
phodiesterase type-5 inhibitors (n=4) or prostacylins (n=1; 
Table). Diuretics were initiated in all patients.
A fatal course of the disease was observed in 4 of the 7 
patients because of right heart failure (n=2), local tumor pro-
gression (n=1), and severe pneumonia (n=1).
Estimated Incidence of MMC-Induced PVOD in 
Patients With Anal Cancer in France
In cancer registries within France, the age-standardized inci-
dence of squamous anal cancer is 0.2 to 0.7 per 100 000 cases 
per year in men, and 0.7 to 1.2 per 100 000 cases per year 
in women.15 Thus, we estimated that a maximum of 600 new 
cases of anal cancer are diagnosed each year in France. In the 
French PH Network, we diagnosed 7 cases of MMC-induced 
PVOD in a 3-year period. The estimated incidence of PVOD 
in patients displaying anal cancer was 3.9 of 1000 patients per 
year and was higher than the incidence of PVOD in the general 
population, which is estimated at 0.5/million persons per year. 
The incidence of PVOD in the population that have anal cancer 
is, therefore, >5000 higher than in those with idiopathic PVOD. 
Indeed, not all patients that displayed anal cancer received 
MMC, which led to potential underestimation of the incidence 
of MMC-induced PVOD. Unfortunately, the exact number of 
patients treated with MMC in France was not available.
MMC-Induced PH in Rats With Pulmonary 
Vascular Lesions Resembling PVOD Lesions
When male and female rats were injected with a single dose 
of 4 mg/kg MMC, they developed PH. This was evident at 
24 days later by a significant increase in mPAP, a decrease in 
CO, increased total pulmonary resistance, and compensatory 
Table.  Characteristics of the 7 Patients With MMC-Induced PVOD Identified in the French PH Network
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age at diagnosis, y 53 47 42 51 59 54 54
Sex, M/F F M F F F F F
Delay between initiation of 
chemotherapy and PVOD, mo
5 6 4 2 4 4 12
Chemotherapy regimen Mitomycin Mitomycin
5-FU
Mitomycin
5-FU
Mitomycin Mitomycin
5-FU
Mitomycin
5-FU
Mitomycin
5-FU
Oxaliplatin
Number of cycles of mitomycin 3 2 2 4 4 2 11
NYHA functional class, I–IV IV III III IV III IV III
6-MWD, m Unable to perform 332 267 Unable to 
perform
240 Unable to perform 230
mPAP, mm Hg 41 36 39 64 46 37 43
PCWP, mm Hg 2 2 5 15 10 6 3
CI, L∙min–1∙m–² 2.1 1.6 2.8 3.5 4 1.9 2.1
PVR, WU 11.2 13.6 8.2 8.2 5.5 11.3 12.1
Svo
2, % 49 61 54 – 48 39.5 62
Pao
2, kPa (in room air) 6.1 7.7 NA 7.1 6.6 8.2 (5l/min O2) 7.1
DLCO, % theo NP 21 30 36 51 NP 34
BNP, ng/L (<100 ng/L) 641 951 452 1536 1048 716 1279
Chest HRCT 
  Septal lines Yes Yes Yes Yes Yes Yes Yes
  Ground-glass opacities Yes Yes Yes Yes Yes Yes Yes
  Lymph node enlargement Yes Yes Yes Yes Yes Yes Yes
PAH therapy ERA, PDE-5i ERA, PDE-5i ERA, PDE-5i ERA ERA, PDE-5i ERA/ corticosteroids Epoprostenol
Follow-up Death from right  
heart failure
Death from 
severe 
pneumonia
Death from tumor 
progression and 
PH 
Death from right 
heart failure
Alive after  
3 mo
Alive after  
3 wk
Alive after  
12 mo
Mutations in EIF2AK4 gene No – No – – No No
Mutations in BMPR2 gene No No No No
BMPR2 indicates bone morphogenetic protein receptor, type II; BNP, brain natriuretic peptide; CI, cardiac index; CO, cardiac output; DLCO, diffusing capacity of the 
lung for carbon monoxide; EIF2AK4, eukaryotic translation initiation factor 2 alpha kinase 4; ERA, endothelin receptor antagonists; 5-FU, 5-fluorouracil; HRCT, high-
resolution computed tomography; NYHA, New York Heart Association; PCWP, pulmonary capillary-wedge pressure; PDE-5i phosphodiesterase type-5 inhibitors; PVOD, 
pulmonary veno-occlusive disease; RAP, right atrial pressure; 6-MWD, 6-minute walk distance; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial 
hypertension; PVR, pulmonary vascular resistance; Svo
2, mixed oxygen saturation; and WU, Wood units. 
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RV hypertrophy, as quantified by the Fulton index (RV/
(LV+S)) (Figure 2). Because of the small size of our experi-
mental groups, we did not find a significant statistical differ-
ence between being male versus female using the log-rank 
test (data not shown). However, female rats seem to be more 
sensitive to the toxicity of MMC exposure because only a few 
(3/10) survived until the end point of the study (in comparison 
with 8/10 males surviving).
Specific lesions of human PVOD include septal-vein 
and preseptal-venule muscularization and fibrous occlusion; 
however, another important sign is focal capillary prolifera-
tion within the interstitium. In comparison with the controls 
(Figure 3A and 3B), we observed severe pulmonary vascu-
lar remodeling in rats with MMC-induced PH; this included 
(1) smooth muscle cell hypertrophy/hyperplasia in pulmo-
nary arteries (Figure 3C), (2) neomuscularization of the 
small distal and normally not muscularized pulmonary ves-
sels (Figure 3D), (3) vasculitis of the pulmonary arteries and 
veins (Figure 3E), (4) foci of pulmonary edema and capillari-
tis (Figure 3F and 3G), and (5) foci of alveolar wall thick-
ening that resembled pulmonary capillary hemangiomatosis 
(Figure 3H).
Because female rats were more sensitive to MMC, we 
decided to treat females twice with lower doses (ie, 2 and 3 
mg/kg) of MMC, at 1 week apart. Rats exposed twice to MMC 
were too fragile to undergo invasive hemodynamic measure-
ments, so we evaluated the severity of PH by using the Fulton 
Index (Figure I in the online-only Data Supplement). At 30 
Figure 1. High-resolution CT of the chest in a patient displaying MMC-induced PVOD. A, Presence of septal lines and centrilobular 
ground-glass opacities. B, subcarinal lymphadenopathy. CT indicates computed tomography; MMC, mitomycin-C; and PVOD, pulmonary 
veno-occlusive disease.
Figure 2. MMC induces PH in rat. A, Mean pulmonary arterial pressure (mPAP: in mm Hg) in control and MMC-exposed rats (MMC). 
B, Cardiac output (CO in mL/min). C, Total pulmonary vascular resistances (TRP: in mm Hg∙mL–1∙min–1). D, Right ventricular hypertrophy 
characterized by the Fulton Index (FI = right ventricle [RV]/left ventricle [LV] + septum [S] weight ratio). Black dots: males; red dots: 
females. Females were more sensitive to MMC than males: only 3 of 10 of females survived in comparison with 8 of 10 of males by day 
24 after 4 mg/kg MMC. Because of the severe PH, we could only obtain hemodynamic data from 1 female. Dot plots with medians; 
***P<0.001, ****P<0.0001. MMC indicates mitomycin-C; and PH, pulmonary hypertension.
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days after the first injection, female rats exposed to 3 mg/kg 
MMC had severe PH in comparison with controls and female 
rats given 2 mg/kg MMC. In animals that received 3 mg/kg 
MMC, we found severe obstructive lesions with pulmonary 
artery adventitial and intimal thickening, and medial hyper-
trophy/hyperplasia (Figure 4A through 4D). There was also 
intimal thickening and eosinophilic inflammation of pulmo-
nary veins (Figure 4E through 4H). More distally, in the ves-
sels accompanying the terminal bronchioles, we found medial 
hypertrophy of the small pulmonary arteries and severe inti-
mal lesions of small pulmonary veins still associated with 
extensive adventitial accumulation of eosinophils (Figure 4M 
through 4P) in comparison with control vessels (Figure 5I 
through 5L). MMC-exposed arterioles (characterized by 
separated internal and external elastic lamina) and venules 
(characterized by a single external elastic lamina) arranged 
in the lung parenchyma harbored neomuscularization, neo-
intimal thickening, and eosinophilic inflammation (Figure 4Q 
through 4S), as did the distal pulmonary arteries and veins. In 
contrast, microvessels (arterioles and venules) present in the 
control rats’ parenchyma were indistinguishable (both were 
characterized by extremely thin walls; Figure 5T). The foci of 
pulmonary edema and capillaritis (Figure 4U and 4V) and the 
foci of alveolar wall thickening were suggestive of pulmonary 
capillary hemangiomatosis in the vicinity of the remodeled 
venule in MMC-exposed animals (Figure 4W and 4X): this 
strengthened the resemblance of this experimental model of 
PH to that of human PVOD.
To ascertain the postcapillary nature of the pulmonary 
microlesions found in MMC-exposed animals, we performed 
a retrograde injection of microbeads from the LV into the 
venous bed of the lungs. The 10-μm diameter of the beads 
did not allow them to cross the capillary bed. In control rats, 
bead-containing vessels displayed loose and slack walls and 
large lumens characteristic of veins and venules (Figure 5A 
through 5C). In MMC-exposed rats, the beads were plugged 
in severely remodeled microvessels, which we identified as 
postcapillary vessels (Figure 5D and 5F).
PVOD is characterized by numerous patchlike foci of cap-
illary hemangiomatoses, which are produced by microvascular 
Figure 3. MMC induces pulmonary vascular 
remodeling in the rat, with significant pulmonary 
venous and capillary involvement that is highly 
suggestive of PVOD. A to B, Control lungs.  
C through H, MMC-exposed lungs. A, Control 
pulmonary arteries (arrows). B, Control distal 
microvessels (arrows, arterioles and venules are 
indistinguishable). C, Pulmonary artery with medial 
hypertrophy/hyperplasia. D, Neomuscularization of 
small distal, normally not muscularized, pulmonary 
microvessels. E, Vasculitis of pulmonary artery 
(arrow) and vein (arrowhead). F and  
G, Foci of pulmonary edema and capillaritis.  
H, Foci of alveolar wall thickening suggestive of 
pulmonary capillary hemangiomatosis. A through 
H, Hematoxylin-eosin-safran stained paraffin-
embedded tissue sections. A through D, G: Scale 
bar, 50 μm. E and H: Scale bar, 100 μm. F: Scale 
bar, 200 μm. MMC indicates mitomycin-C; and 
PVOD, pulmonary veno-occlusive disease.
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endothelial-cell proliferation (Figure 6B), and was almost 
undetectable in the control rats’ lung parenchyma (Figure 6A). 
To examine cell proliferation in rats, we visualized the 
incorporation of exogenously supplied EdU to identify cells 
undergoing DNA replication. In control lung parenchyma, we 
observed very few EdU-positive cells (Figure 6C), whereas 
Figure 4. Rats exposed twice to 3 mg/kg MMC had severe pulmonary arterial, capillary, and venous remodeling; the histopathologic pattern of 
PVOD. A through H, M through S, and U through X, MMC-exposed lungs. I through L and T, Sex- and age-matched control lungs. A and  
B, Intimal remodeling (white double-headed arrow) of the muscular pulmonary artery accompanying the bronchus (external diameter >200 μm). 
Note the internal elastic (*). C and D, Adventitial remodeling (white double-headed arrow). Note the medial smooth muscle cells (α-smooth muscle 
actin, stained red; C) and fibrous remodeling of the adventitia (collagen in orange; D). E and F, Intimal thickening of pulmonary veins (external 
diameter >100 μm). G and H, Perivascular eosinophilic inflammation of the pulmonary vein (arrows). I, Control small pulmonary artery and vein 
(<100 μm). J, Control small pulmonary artery accompanying a terminal bronchiole with very thin muscular media. K and L, A small pulmonary 
vein with a typical thin loose, slack wall and a large lumen. M, A MMC-exposed small pulmonary artery accompanying a terminal bronchiole with 
hypertrophied muscular medium that is delimited by apparent internal and external elastica. O and P, A MMC-exposed small pulmonary vein, 
typically delimited by a single elastica, with severe lumen obstruction and extensive perivascular eosinophilic inflammation. Q–S, MMC-exposed 
arteriole (R) and venule (S) arranged in lung parenchyma and harboring neomuscularization, neointimal thickening, and eosinophilic inflammation, 
as were the distal pulmonary arteries and veins (N, O). T, Microvessels (arterioles and venules, *) present in the control parenchyma are 
indistinguishable. U and V, Foci of pulmonary edema and capillaritis. W and X, Foci of alveolar wall thickening suggestive of pulmonary capillary 
hemangiomatosis in the vicinity of the remodeled venule (*). A, B, D through X, Hematoxylin-eosin-safran + orcein staining, and C, α-smooth 
muscle actin immunostained paraffin-embedded tissue sections. A, C, D, E, G, I, M, Q, T, U, W: Scale bar, 100 μm. F, H, J, K, N, O, R, S, X: 
Scale bar, 50 μm. B, L, P: Scale bar=20 μm. U: Scale bar, 1000 μm. MMC indicates mitomycin-C; and PVOD, pulmonary veno-occlusive disease.
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there was a focus of intense microvascular endothelial-cell pro-
liferation (parenchymal CD34+EdU+ cells) in MMC-exposed 
rats (Figure 6C through 6G). We also saw endothelial (luminal 
CD34+EdU+ cells) proliferation in pulmonary venules, which 
was identified by the presence of microbeads (retrograde injec-
tion) in the lumen (Figure 6E). We also observed adventitial-
cell proliferation in the remodeled pulmonary microvessels of 
these animals (Figure 6D and 6F).
Kinetics of MMC-Induced PH in Rats
To assess the time course of PH development in MMC-
exposed rats, we performed echocardiographic analyses at 
the time of MMC injection and then weekly for the 5 weeks. 
Pulmonary artery acceleration time was significantly reduced 
from the fourth week onward in comparison with the controls 
(medians, 25 versus 39 ms, P=0.0007) and baseline values 
(medians, 25 versus 30 ms, P=0.0035). CO was significantly 
Figure 6. Microvascular endothelial cell 
(MEV) proliferation in human PVOD and 
MMC-induced PVOD-like PH in rats. A and 
B, Human lungs, PCNA IHC stains (red 
stain=proliferating cells; blue counterstain, 
hematoxylin) on paraffin-embedded tissue 
sections. C through G, Rat lungs, click-iT 
EdU stain (green nuclei=proliferating cells) 
with CD34 (endothelial cells, in red) and 
α-smooth muscle actin (smooth muscle 
cells/α-SMA, in white) immunofluorescent 
staining of frozen sections and confocal 
imaging. Counterstain=4′,6-diamidino-
2-phenylindole (DAPI). A, Control human 
lung parenchyma displays very little 
cellular proliferation. B, Pulmonary capillary 
hemangiomatosis (PCH) from explanted 
PVOD lung is characterized by intense MEV 
proliferation. C, Control rat-lung parenchyma 
displays very little MEV proliferation. D 
through G, PCH-like foci from MMC-
exposed rats display intense MEV 
proliferation (red cells with green nucleus). 
Note the microvessels coated with α-SMA 
(neomuscularization) displaying adventitial-
cell proliferation (arrows); the venule is 
identified by the red autofluorescent 
microbead (*, retrograde injection), 
and displays important endothelial-cell 
proliferation. A and B: Scale bar, 100 μm. 
C through F: Scale bar, 50 μm. G: Scale 
bar, 20 μm. EdU indicates 5-ethynyl-2′-
deoxyuridine; IHC, immunohistochemistry; 
MMC, mitomycin-C; PCNA, proliferating 
cell-nuclear antigen; and PVOD, 
pulmonary veno-occlusive disease.
Figure 5. Identification of veins and venules by retrograde injection of microbeads from the left ventricle. A through C, Control lungs.  
D through F, MMC-exposed lungs. A, Large field of a control lung. Br indicates bronchus; A, artery; and V, vein. Only the vein contains green 
beads. B and C, Control venules with green beads. Control venules display a loose and slack wall and a large lumen. D, E, and F, Vein and 
venules of MMC-exposed lungs. Beads allow identification of severely remodeled vessels as postcapillary vessels. A through F, Hematoxylin-
eosin–stained frozen sections. A and D: Scale bar, 100 μm. B, E, and F: Scale bar, 50 μm. C: Scale bar, 20 μm. MMC indicates mitomycin-C.
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reduced from the fourth week in comparison with the controls 
(medians, 73 versus 110 mL/min, P=0.0008) and baseline 
values (medians, 73 versus 91 mL/min, P=0.0056). The RV 
wall thickness was significantly increased in comparison with 
control (medians, 0.08 versus 0.06 cm, P=0.0187) and base-
line values (medians, 0.08 cm versus 0.06 cm, P=0.0047). The 
ratio of RV to LV increased from the fifth week in comparison 
with baseline values (medians, 0.58 versus 0.52, P=0.0326). 
For some animals, we managed to have both echo readings 
and direct hemodynamic measurement by catheterization: 
both gave comparable results (Figure II in the online-only 
Data Supplement).
MMC-Induced PVOD in Rats With Reduced GCN2 
Expression and Disruption of smad1/5/8 Signaling
On the one hand, our group demonstrated that EIF2AK4 
(coding GCN2) is the major gene linked to PVOD4; on 
the other hand, BMPR2 mutations are strongly related to 
PAH susceptibility/development.16 We measured the pro-
tein expression of these 2 genes in MMC-exposed rats. 
We found that the pulmonary protein level of BMPRII 
was unaffected in these animals, whereas protein levels of 
GCN2 were decreased (Figure 7A). Moreover, we found 
that GCN2 pulmonary protein levels were inversely related 
to the dose of MMC exposure: a high dose of MMC was 
related to higher PH and lower GCN2 levels (Figure 7B). 
Accordingly, explanted lungs from heritable PVOD 
showed null expression of GCN2, whereas BMPRII levels 
remained not statistically different from the control lungs 
(Figure 7C).
Although the pulmonary protein level of BMPRII was 
unaffected in MMC-exposed rats and in human PVOD, 
both conditions were characterized by an almost total 
disruption of smad1/5/8 signaling (Figure 7D and 7E). 
Because the dysfunction of GCN2 signaling is crucial 
to the development of PVOD, we wondered if this path-
way could modulate the smad cascade in the absence of 
BMPRII alteration, and thus explain, at least in part, our 
results. We used Ingenuity Pathway Analysis software, a 
Web-based mammalian biology knowledgebase and anal-
ysis tool used for genomic data analysis, to decipher the 
connections between both signals. We found a complex and 
unrevealed interplay between both signals (Figure III in the 
online-only Data Supplement).
Amifostine Prevented PVOD Development When 
Used in Combination With MMC
Amifostine ameliorated MMC-induced PVOD with nota-
ble improvement in survival (Figure 8A), RV hypertrophy 
(Figure 8B), and pulmonary hemodynamics (increase in CO 
with a decrease in total peripheral vascular resistance) in 
MMC + amifostine-treated rats (Figure 8C through 8E). The 
decrease of total pulmonary resistance in MMC + amifos-
tine–treated rats was linked to a decrease in resistive fully 
muscularized distal microvessels, and an increase in low-
resistance nonmuscularized distal microvessels (Figure 8F 
through 8H). The percentage of occluded distal microves-
sels was significantly lowered in the amifostine group 
(Figure 8I).
Discussion
Since 2012, the French PH Network has identified 7 cases 
of PVOD in patients treated with MMC for squamous anal 
cancer, which is the major indication for MMC in France. 
These PVOD patients typically present with precapillary 
PH, radiological abnormalities seen on high-resolution CTs 
of the chest, a low diffusing capacity of the lung for carbon 
monoxide, and severe hypoxemia. These patients had severe 
symptoms and marked hemodynamic symptoms at diagnosis. 
According to previous reports, the prognosis of these PVOD 
patients appeared very poor, and 4 of 7 seven patients died 
shortly after diagnosis of acute right heart failure or tumor 
progression.17–19 Indeed, 2 of the 7 patients received only 
MMC, which strongly reinforced the hypothesis of a direct 
link between MMC and PVOD. Nevertheless, these findings 
should not obscure the possibility that several other drugs may 
also have had similar effects as MMC. A recently published 
analysis of the association between chemotherapeutic agents 
and PVOD suggests that alkylating agents may represent a 
drug class at risk for PVOD.6
In France, treatment with MMC is nearly exclusively used 
in the setting of anal cancer. Therefore, we used the number 
of patients treated in France for this indication and extrapo-
lated these results to obtain an incidence rate for PVOD after 
exposure to MMC. The lower estimated incidence of PVOD in 
patients displaying anal cancer is excessively high (3.9/1000 
per year) in comparison with the incidence of PVOD in the 
general population (<1/million per year). However, MMC-
induced PVOD has also been reported in the setting of 
non–small-cell lung cancer,18 gastric adenocarcinoma,20 and 
cervical carcinoma.5 MMC lung toxicity is mainly caused by 
acute or chronic interstitial lung diseases, with an estimated 
incidence of 1.8%.21
In this study, we have confirmed the role of MMC in the 
development of pulmonary vascular lesions in animal mod-
els. In rats, MMC exposure induced pulmonary hyperten-
sion with pulmonary vascular lesions that resembled PVOD 
lesions: ie, (1) foci of alveolar wall thickening suggestive of 
pulmonary capillary hemangiomatosis, (2) foci of pulmonary 
edema and capillaritis, (3) vasculitis of pulmonary veins and 
arteries, (4) intimal and adventitial remodeling of pulmonary 
arteries and veins (especially after 2 exposures to MMC), (4) 
neomuscularization of small distal pulmonary microvessels, 
(5) venule obstruction, and (6) medial hypertrophy/hyper-
plasia of pulmonary arteries. The postcapillary nature of the 
pulmonary microlesions found in MMC-exposed animals was 
ascertained through retrograde injection of microbeads from 
the LV into the venous bed of the lungs. Subsequently, the 
beads became plugged into severely remodeled microvessels 
of treated rats, and were identified as postcapillary vessels. 
MMC-exposed lungs also displayed foci of intense microvas-
cular endothelial-cell proliferation, mimicking the patchlike 
foci of capillary hemangiomatosis found in PVOD. We also 
observed endothelial and adventitial cell proliferation in the 
remodeled pulmonary microvessels of these animals.
We assessed the time course of PH development in MMC-
exposed rats through echocardiographic analyses at the 
time of MMC injection, and then every week for 4 weeks. 
Echocardiographic abnormalities appeared from the fourth 
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week of follow-up. Females were more susceptible to MMC 
toxicity. Interestingly, although the female/male (F/M) ratio 
for anal cancer is 2:1 in the general population in France,15,22 
the sex disequilibrium for MMC-induced PVOD was much 
stronger (F/M ratio: 6:1). Of note, the only man affected in 
our series was also HIV infected, a risk factor for both PAH 
and anal cancer, whereas all 6 women were HIV negative. 
Even if there is no pathophysiological explanation to date, 
experimental and human data suggest an increased suscepti-
bility of females to MMC-induced PVOD. The reasons for the 
association between female sex and MMC toxicity are poorly 
understood.
Only a small proportion of patients who received MMC 
(alone or in combination with other chemotherapeutic agents) 
will develop PVOD, although all the rats developed pulmo-
nary venous remodeling in this study. This observation is in 
accordance with the low proportion of patients who develop 
PAH in other forms of drug-induced PAH (appetite suppres-
sants, <1/10 00023; dasatinib, <1/10024), suggesting an individ-
ual susceptibility to pulmonary vascular drugs. In our series, 5 
patients received MMC with 5-fluorouracil and 1 patient had a 
comorbid HIV infection, a well-known cause of PAH. We can-
not exclude that multiple hits may explain the development 
of PVOD in these patients. Nevertheless, the occurrence of 
PVOD in 2 patients receiving only MMC (without any other 
known PAH risk factors) and the data obtained in animal 
models, suggest a direct role of MMC in pulmonary venular 
lesions. The multiple hits hypothesis has also been proposed 
in other pulmonary vascular diseases such as drug-induced 
PAH or heritable PAH. This susceptibility is not explained by 
mutations in EIF2AK4 gene4 in our patients. These results do 
not exclude the involvement of other genetic characteristics 
Figure 7. Pulmonary levels of BMPRII 
GCN2 and p-smad1/5/8 in human PVOD 
and MMC-induced PVOD-like PH in rats as 
measured by Western blot analysis (WB). 
β-Actin was used as loading control. Right 
panels: quantification of the WBs.  
A, BMPRII and GCN2 protein expression 
in lungs from controls or rats exposed to 
a single dose of MMC (4 mg/kg). B, GCN2 
protein expression in lungs from controls 
or rats exposed to 2 low (2 mg/kg) or 
high (3 mg/kg) doses of MMC. C, BMPRII 
and GCN2 protein expression in lungs 
from controls or human heritable PVOD 
(hPVOD) explanted lungs. D, p-smad1/5/8 
phosphoprotein expression in lungs 
from controls or rats exposed to a single 
dose of MMC (4 mg/kg). E, p-smad1/5/8 
phosphoprotein expression in lungs from 
controls or hPVOD explanted lungs. Box 
Plot (Min to Max); *P<0.05, ****P<0.0001, 
n=3–4/group. MMC indicates mitomycin-C; 
PH, pulmonary hypertension; and PVOD, 
pulmonary veno-occlusive disease.
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and particular susceptibility polymorphisms in other genes. It 
is well accepted that several risk factors, such as gene muta-
tions, autoimmunity, drugs, and infection, may induce PAH. 
Similarly, we hypothesize that PVOD could result from dif-
ferent triggers, including chemotherapeutic agents, connective 
tissue disease (such as systemic sclerosis), or genetic suscepti-
bility (biallelic EIF2AK4 mutations).
We cannot exclude that an associated treatment, such as 
chemoprotectant (amifostine) or corticosteroids, may also 
modulate pulmonary vascular injury and reduce the side 
effects of MMC toxicity in patients. None of our patients 
received amifostine. To investigate preventive strategies, we 
evaluated the impact of amifostine in MMC-induced PVOD 
in rats. In this animal model, amifostine markedly improved 
survival and significantly decreased pulmonary distal vascular 
remodeling, total pulmonary resistance, RV hypertrophy, and 
RV function. These experimental data suggest that cytoprotec-
tive agents may have an ability to prevent PVOD in patients 
treated with MMC.
Interestingly, we demonstrated in animal models that 
MMC induced a PVOD-like disease and depletion of pulmo-
nary GCN2 content in a dose-dependent manner. Although the 
pulmonary protein level of BMPRII was unaffected in MMC-
exposed rats and in human PVOD, both conditions were char-
acterized by almost total disruption of smad1/5/8 signaling. 
Using Ingenuity Pathway Analysis, we found a complex and 
unrevealed interplay between both signals, which improves 
our understanding of PH/PVOD pathobiology and justifies 
further investigations.
PVOD patients have a poor outcome, with a worse prog-
nosis than PAH patients. To date, there is no cure for this 
devastating disease, and the use of specific PAH therapies 
Figure 8. MMC-induced PVOD is partially 
prevented by amifostine pretreatment. 
Amifostine was given IP at 200 mg/kg for 30 
minutes before 3 mg∙kg–1∙wk–1 for 2 weeks of 
MMC. Animals were euthanized at 4 weeks after 
the second MMC injection. Survival, right heart 
hypertrophy and hemodynamic parameters 
were evaluated. A, Survival curves for MMC, 
and MMC + amifostine groups. B, Fulton Index 
(FI = right ventricle [RV]/ left ventricle [LV] + 
septum [S] weight ratio). C, Right ventricular 
systolic pressure (RVSP) in mm Hg. D, Cardiac 
output (CO) in mL/min. E, total pulmonary 
resistances (TPR) in mm Hg∙mL–1∙min–1. MMC-
induced pulmonary vascular remodeling 
is alleviated by amifostine pretreatment. 
Muscularization of distal vessels (DV; <50 μm) 
was evaluated. F, % of nonmuscularized (NM) 
DV. G, % of partially muscularized (PM) DV. 
H, % of fully muscularized (FM) DV. I, % of 
occluded DV. Dot plots with medians; *P<0.05, 
**P<0.01, ****P<0.0001. MMC indicates 
mitomycin-C; and PVOD, pulmonary veno-
occlusive disease.
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(prostacyclin, endothelin-receptor antagonists, or phosphodi-
esterase type 5 inhibitors) may induce life-threatening pulmo-
nary edema.1,2,25,26 Thus, the benefits of these treatments have 
not been demonstrated in PVOD; the only recommended treat-
ment is lung transplantation for eligible PVOD patients.1,2,27 
MMC-induced PVOD in rats represents a specific model 
for pulmonary venous involvement associated with reduced 
GCN2 expression; this suggests that it could represent a gen-
eral model for idiopathic, heritable, or drug-induced PVOD. 
Indeed, this model constituted a unique opportunity to learn 
more about the pathophysiology of PVOD and to test an inno-
vative therapy.
MMC is an alkylating agent with antibiotic and antitumor 
characteristics. It has been previously used to treat pancreatic, 
stomach, and breast cancers; however, anal cancer remains the 
main indication for this drug therapy.28 Complications from 
this treatment are bone marrow toxicity, renal damage, and 
interstitial lung diseases, caused by extensive tissue damage. 
Pulmonary vascular injuries, including alterations to endo-
thelial cells, have also been reported.29 MMC-related lung 
toxicity is a dose-dependent side effect.30 It was thought that 
MMC could have selective toxicity on cancer cells through 
specific tumor expression of MMC-activating enzymes, such 
as NAD(P)H:quinone oxidoreductase (NQO1). NQO1 is a 
flavoenzyme that catalyzes the 2-electron reduction of qui-
nones and related compounds, such as MMC. NQO1 has been 
shown to be overexpressed in many types of cancer. However, 
Siegel et al31 also demonstrated a high level of NQO1 protein 
expression in normal lung respiratory epithelium and pulmo-
nary vascular endothelium. Hence, vascular cells in normal 
lungs contain marked NQO1 protein expression and may be 
damaged by MMC therapy, leading to specific pulmonary vas-
cular toxicity.31
The development of lung damage induced by MMC begins 
with irregular thickening of the endothelial cells of the capil-
laries and progresses to the release of a surfactant and to the 
activation of alveolar macrophages.32 In a woman treated with 
MMC plus 5-fluorouracil, who developed progressive and 
fatal PH, scanning electron microscopy of the cast blood ves-
sels showed distortion and destruction of alveolar capillaries 
that prohibited the passage of erythrocytes. Extensive capil-
lary damage and venous occlusion were observed, resulting in 
excessive new capillary formation, sometimes in angiomatoid 
configurations, and hypertrophy of pulmonary veins and arter-
ies.33 At the molecular level, it has been suggested that MMC-
induced pulmonary vascular dysfunction may be related to its 
bifunctional alkylating property. Cultured pulmonary-artery 
endothelial cells exposed to MMC showed similar growth 
arrest and morphological alterations to monocrotaline pyr-
role, another bifunctional alkylating substance known to be a 
potent trigger for experimental PH in rats.29,34 Both alkylating 
agents may compromise the capacity for replicative repair of 
endothelial cells, accounting for the delayed vascular injury 
induced by these molecules. Moreover, it has been shown 
that MMC results in a marked decrease in the biosynthesis 
of prostacyclin in cultured human umbilical cord vein endo-
thelial cells.35 Last, MMC has the characteristics expected of 
a bioreductive alkylating agent: activation of alkylating spe-
cies occurs more readily under hypoxic conditions, and the 
drug is selectively cytotoxic to hypoxic cells.36 The underlying 
hypoxic condition may thus increase the pulmonary vascular 
side effects of MMC.
Biallelic mutations of the EIF2AK4 gene (coding GCN2) 
have been identified as the predisposing gene related to heri-
table PVOD.4 According to our results, we can hypothesize 
that MMC depletes GCN2 in the lungs and mimics PVOD 
induced by EIF2AK4 mutations. Interestingly, Wilson et al37 
have demonstrated that the loss of GCN2 promotes oxida-
tive stress and inﬂammatory-mediated DNA damage during 
asparaginase therapy; this suggests that patients with reduced 
GCN2 may be at risk of developing hepatic complications 
during asparaginase treatment. Our results may suggest that 
MMC-induced GCN2 depletion could favor similar oxidative 
and inflammatory pulmonary injuries.
Recently, Lathen et al38 demonstrated that the ERG–
APLNR axis may play a role in the control of pulmonary-
venule endothelial proliferation. These authors demonstrated 
that Erg binds to and serves as a transcriptional activator of 
the G-protein–coupled receptor gene, Aplnr, and that the 
knockout of either Erg or Aplnr results in pulmonary venous–
specific endothelial proliferation in vitro.38 Indeed, mice with 
a homozygous deletion of Erg or Aplnr develop remodeled 
postcapillary pulmonary venules. Interestingly, in human 
PVOD lung tissues, levels of ERG protein, APLNR-mRNA, 
and protein were significantly decreased in comparison with 
control lungs.38 Unlike our animal model of MMC-induced 
PVOD, which was characterized by a dose-dependent deple-
tion in pulmonary GCN2 content, the authors did not find any 
difference in the expression of GCN2 in lung tissues from 
animals with homozygous or heterozygous deletion of Erg 
or Aplnr.38 These results may suggest that animal models of 
PVOD, based on the deletion of Erg or Aplnr, may induce pul-
monary venous lesions independently of the EIF2AK4 path-
way, the main predisposing gene factor for heritable PVOD.4 
Relations between exposure to the alkylating agent EIF2AK4 
and the ERG-APLN axis should better characterize the patho-
physiology of PVOD. Interestingly, Erg-Aplnr–related and 
MMC-induced PVOD models may allow us to address distinct 
aspects of PVOD. The first model is a model of pulmonary 
venular sprouting, whereas the second is an Eif2ak4-related 
model that reproduces the whole spectrum of PVOD lesions.
In conclusion, 7 cases of MMC-induced PVOD were iden-
tified in the French PH Network in a 3-year period. Physicians 
should be aware of this rare complication of MMC therapy. 
Unexplained dyspnea after MMC therapy should raise the pos-
sibility of underlying pulmonary vascular toxicity and PVOD 
should be screened for through a noninvasive workup (diffus-
ing capacity of the lung for carbon monoxide, blood gases, 
Doppler echocardiography, and a high-resolution CT of the 
chest). Possible cases of PVOD at screening should undergo 
right heart catheterization to confirm and evaluate PH severity. 
Our preclinical data confirm the links between MMC expo-
sure and pulmonary venous lesions, and open up a new area of 
research. MMC-induced PVOD in rats is a novel animal model 
for human PVOD, which allows us to test innovative strate-
gies to prevent and treat this devastating disease. Amifostine 
prevents MMC-induced PVOD in rats and should be tested as 
a preventive therapy of MMC-induced PVOD in humans.
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CLINICAL PERSPECTIVE
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension characterized by a progressive occlu-
sion of the small pulmonary veins by fibrous tissue and intimal thickening. Recently, biallelic mutations in the eukaryotic 
translation initiation factor 2-αkinase 4 (EIF2AK4) gene have been demonstrated as the major genetic cause of heritable 
PVOD. Apart from genetic predisposition, other risk factors have also been identified including cases induced by chemo-
therapeutic agents. In the present study, we report 7 new cases of mitomycin-C–induced PVOD identified in the French 
Pulmonary Hypertension Registry and reported to the French pharmacovigilance agency. All patients had a history of squa-
mous anal cancer and were treated with mitomycin-C alone or in association with 5-fluorouracil. The estimated annual 
incidence of PVOD in the French population with anal cancer was 3.9 of 1000 patients, which is much higher than the inci-
dence of PVOD in the general population (0.5/million per year). Physicians should thus be aware of this rare complication 
of mitomycin-C therapy, and unexplained dyspnea in this condition should raise the possibility of underlying pulmonary 
vascular toxicity. In addition, intraperitoneal administration of mitomycin-C induced PVOD in rats, as demonstrated by 
pulmonary hypertension at right heart catheterization with major remodeling of small pulmonary veins and foci of intense 
microvascular endothelial-cell proliferation of the capillary bed. This was associated with a reduced pulmonary expression 
of GCN2, the protein coded by EIF2AK4 gene. This animal model mimicking human PVOD opens up a new area of research 
and represents a unique opportunity to test innovative strategies in this devastating disease.
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SUPPLEMENTAL MATERIAL 
 
 
 
Expanded Methods 
 
In vivo study design 
Rats were housed at the Faculty of Pharmacy of Châtenay-Malabry (ANIMEX platform, Châtenay Malabry, 
France). Experiments were conducted according to the European Union regulations (Directive 86/609 EEC) for 
animal experiments and complied with our institution's guidelines for animal care and handling. The animal 
facility is licensed by the French Ministry of Agriculture (agreement N° B92-019-01). This study was approved 
by the Committee on the Ethics of Animal Experiments CEEA26 CAP Sud. Animal experiments were supervised 
by Dr. Frederic Perros (agreement delivered by the French Ministry of Agriculture for animal experiment N° 
A92–392). All efforts were made to minimize animal suffering. 
Male and female Wistar rats (Janvier, eight weeks old) were subjected to different protocols to evaluate sex 
differences, dose–response relationships and the kinetics of PH development after MMC exposure. 
Protocol 1: Gender-specific susceptibility. Male and female rats were randomly divided into saline (control, 
n=5) or MMC-exposed groups (Ametycin, Sanofi, 4 mg/kg, i.p., n=10). We performed haemodynamic 
measurements, assessed right-ventricle hypertrophy and tissues were collected at 24 days after the injection. 
Protocol 2: Dose–response relationships. Females, which harboured a more severe response to MMC (than 
males), were used to study MMC-induced severe pulmonary vasculopathy induced by fractioned lower doses. 
Rats were randomly divided into saline (control, n=5) or MMC-exposed groups: i.e., 2 and 3 mg/kg/week/2 
weeks (i.p. n=10 for each dose). Rats were sacrificed at 30 days after the first injection. Haemodynamic 
measurements were made, right-ventricle hypertrophy was assessed and tissue samples were collected. 
Protocol 3: Kinetics of PH development. Female rats were randomly divided into saline (control, n=5) or MMC-
exposed groups (3 mg/kg/week/2 weeks, i.p., n=10). We evaluated the haemodynamics using 
echocardiography at baseline, and at 1, 2, 3, 4 and 5 weeks after the first MMC injection (n=5–10 rats for each 
time point).  
Protocol 4: Prevention study. Amifostine was given i.p. at 200mg/kg 30 minutes prior to 3 mg/kg/week/2 
weeks of MMC (n=15). This group was compared to MMC only-exposed group (MMC, 3 mg/kg/week/2 weeks, 
n=25). Survival was evaluated over five weeks. Survivors were sacrificed five weeks after the second CP 
injection for hemodynamic, RVH measurements, and tissue collection. 
Regarding the doses used in this study, Warren et al
1
 used MMC-DNA adducts as an indicator for the host’s 
exposure and capacity for metabolic activation, detoxification, and DNA repair. In mice, they found that MMC 
(4 mg/kg) was roughly equivalent to a conventional human chemotherapy dose. In rats, Mizushima et al
2
 found 
that 2, 3, and 4 mg/kg MMC induced 0, 33 and 30% mortality, respectively at 28 days. Those doses 
corresponded in this species, to high-dose chemotherapy. We decided to use 4 mg/kg and lower (3 and 2 
mg/kg) in rats as they seemed to be in the equivalent range of human chemotherapy. 
As addressed by Andreollo et al
3
, the differences in anatomy, physiology, development and biological 
phenomena must be taken into consideration when comparing time-lapse between rat and human. Rats 
rapidly develop during childhood and become sexually mature at about six weeks old, but reach social maturity 
five to six months later. In adulthood, every month of the animal is approximately equivalent to 2.5 human 
years. Several authors performed experimental studies in rats and estimated 30 days of human life for 
everyday life of the animal
3
. Regarding our observations in humans, the delay between initiation of MMC 
therapy and final diagnosis of PVOD was 5.3 months (range: 2–12 months). It is difficult to compare the 
development of pulmonary vascular damage in animals and in humans, but in each case the development of 
PVOD after exposure to chemotherapeutical drugs is rapid. 
 
Quantification of pulmonary microvessels neomuscularization 
OCT-embedded frozen lungs were sectioned at 6 µm thickness and stained in double immunofluorescence, for 
von Willebrand factor (vWF, Dako) and α-smooth muscle actin (α-SMA, clone 1A4, Sigma). 40 to 60 pulmonary 
microvessels (<50µm) were analyzed and categorized as muscularized when vWF+ endothelial cells in 
microvessels were coated with α-SMA+ smooth muscle cells (fully [FM] or partially [PM] when vessels 
contained at least one cell that was positive for α-SMA but lacked a continuous layer) or non-muscularized 
(NM) in the absence of this coating, to assess the degree of muscularization of these normally non-
muscularized pre- and post-capillary vessels. 
  
Supplementary legends and figures 
 
Supplementary figure 1: MMC induces PH in a dose-dependent manner. Female rats harboured a more severe 
response to MMC than males: thus, they were chosen to study MMC-induced severe pulmonary vasculopathy 
after fractioned lower doses of MMC (2 and 3 mg/kg at one week apart). Rats exposed twice to MMC were too 
fragile to undergo invasive haemodynamic measurements, so we quantified PH though the Fulton Index 
=RV/(LV+S) at 30 days after the first injection. Rats exposed to the higher dose of MMC had more severe right-
ventricular hypertrophy than those exposed to the lower dose. 
Dot plots with means; *: P<0.05, ***: P<0.001 
 
 
Supplementary figure 2: MMC exposed rat displaying features of PH. A. Four chambers view at day 28 with 
ratio RV/LV < 1. B. Four chambers view of the same rat at day 33 with a RV/LV ratio > 1. C. Pulmonary artery 
acceleration time at day 1 (34.3 ms). D. Pulmonary artery acceleration time at day 28 (33.2 ms). E. Pulmonary 
artery acceleration time at day 33 (17.0) with mid-systolic notch. Veloticy-time integral allowed an estimation 
of cardiac output of 45.1ml/min. F. At day 33, a tricuspid regurgitation jet appeared. G. The sPAP estimated 
with tricuspid regurgitation jet was 50 mm Hg. Right heart catheterization in the same rat has given: 
sPAP/dPAP/mPAP as follow 49/13/31 mm Hg and CO of 45.6 ml/min. 
 
Supplementary figure 3: Network analysis using Ingenuity pathway analysis (IPA) software. This figure depicts 
the merged networks of proteins/molecules belonging to the BMPRII (BMPR2 gene), and GCN2 (EIF2AK4 gene) 
signaling. IPA analysis highlights complex and unrevealed interplay between both signaling. Genes/proteins 
implicated in this network:  
ARL4D: ADP-ribosylation factor-like 4D 
BMPR2: bone morphogenetic protein receptor, type II (serine/threonine kinase) 
CDKN2B: cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 
CFDP1: craniofacial development protein 1 
Eif2: elF2, Initiation Factor M1 
EIF2A: eukaryotic translation initiation factor 2A, 65kDa 
EIF2AK3: eukaryotic translation initiation factor 2-alpha kinase 3 
EIF2AK4: eukaryotic translation initiation factor 2 alpha kinase 4 
EIF2B1: eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa 
EIF2B4: eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa 
ERCC3: excision repair cross-complementation group 3 
ERK: p42/44 mapk 
EWSR1: EWS RNA-binding protein 1 
GCN1L1: GCN1 general control of amino-acid synthesis 1-like 1 (yeast) 
HIST1H2BN: histone cluster 1, H2bn 
MARS: methionyl-tRNA synthetase 
SMAD1: SMAD family member 1 
SMAD2: SMAD family member 2 
SMAD3: SMAD family member 3 
SMAD4: SMAD family member 4 
SMAD5: SMAD family member 5 
SMAD6: SMAD family member 6 
SMAD7: SMAD family member 7 
SMAD9: SMAD family member 9 
SMURF1: SMAD specific E3 ubiquitin protein ligase 1 
SMURF2: SMAD specific E3 ubiquitin protein ligase 2 
SNIP1: Smad nuclear interacting protein 1 
STAT1: signal transducer and activator of transcription 1, 91kDa 
TGFBR1: transforming growth factor, beta receptor 1 
TRAP1: TNF receptor-associated protein 1 
WWP1: WW domain containing E3 ubiquitin protein ligase 1 
YY1AP1: YY1 associated protein 1 
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